ChemicalBook >> CAS DataBase List >>Ocrelizumab
Ocrelizumab
- CAS No.
- 637334-45-3
- Chemical Name:
- Ocrelizumab
- Synonyms
- Ocrelizumab;Ocrelizumab (anti-CD20);Research Grade Ocrelizumab;Research Grade Ocrelizumab(DHC90702)
- CBNumber:
- CB23039319
- Molecular Formula:
- C19H16N2O5
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
Last updated:2025-04-17 18:22:24
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | A10SJL62JY |
| NCI Drug Dictionary | ocrelizumab |
| ATC code | L04AA36 |
SAFETY
Risk and Safety Statements
| Hazardous Substances Data | 637334-45-3(Hazardous Substances Data) |
|---|
Ocrelizumab Chemical Properties,Uses,Production
Uses
Treatment of rheumatoid arthritis.
in vivo
Ocrelizumab (7.5 mg/kg; once daily; 18 days; s.c. or i.v.) inhibits lesions in multiple sclerosis mice by inducing B cell exhaustion through antibody dependent cytotoxicity (ADCC)[1]. Ocrelizumab (50 μg; repeat administration on days 7, 14, and 21; i.v.) can reduce B and T cells in the blood, lymph nodes, and spleen of C57BL/6 mice[2].
| Animal Model: | HuCD20 mice with chronic DTH-TLS lesions[1]. |
| Dosage: | 7.5 mg/kg |
| Administration: | Subcutaneous injection (s.c.) or intravenous injection (i.v.); once daily; 18 days; initiated on Days 63, 70 and 75 post lesion induction |
| Result: | Reduced the number of CD19+ cells and MS like lesions in the spleen and lymph nodes of mice. |
| Animal Model: | C57BL/6 mice [2]. |
| Dosage: | 50 μg |
| Administration: | Intravenous injection (i.v.); repeat administration on days 7, 14, and 21 |
| Result: | Reduced the total CD19+ B cells and CD4, CD8 T cells in the blood, spleen, and LN. |
Ocrelizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Ocrelizumab Suppliers
Global( 26)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| AFINE CHEMICALS LIMITED | +86-0571-85134551 | sales@afinechem.com | China | 15395 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| Nanjing Sunlida Biological Technology Co., Ltd. | 025-57798810 | sales@sunlidabio.com | China | 3239 | 55 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9803 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 71829 | 60 |
| ShangHai Biochempartner Co.,Ltd | 17754423994 17754423994 | 2853530910@QQ.com | China | 8011 | 62 |
| Shanghai Biopharmaleader Co., Ltd. | +86 18721201413 | sales@biopharmaleader.com | China | 1720 | 58 |
| BOC Sciences | -- | info@bocsci.com | USA | 0 | 65 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1566 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10356 | 58 |
Ocrelizumab
Research Grade Ocrelizumab(DHC90702)
Ocrelizumab (anti-CD20)
Research Grade Ocrelizumab
637334-45-3